Binex Co

Binex Co EBIT per Share

The EBIT per Share of Binex Co (053030.KQ) as of Oct 27, 2026 is -60.55 KRW. In the previous year, EBIT per Share was -1,202.39 KRW — a change of -94.96% (higher).

EBIT per Share

-60.55KRW

YoY

-94.96%

Last updated:

EBIT per Share of Binex Co is 2025 -60.55 KRW. EBIT per Share of Binex Co was 2024 -1,202.39 KRW. It decreases by -94.96% higher compared to the previous year.

The Binex Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2021
407.84 KRW
Jan 1, 2022
555.52 KRW
Jan 1, 2023
108.83 KRW
Jan 1, 2024
-1,202.39 KRW
Jan 1, 2025
-60.55 KRW
Jan 1, 2026 (e)
-238.43 KRW
Jan 1, 2027 (e)
342.35 KRW
Jan 1, 2028 (e)
707.84 KRW
The Binex Co EBIT per Share history
YEAREBIT per ShareYoY
est707.84KRW+106.76%
est342.35KRW-243.59%
est-238.43KRW+293.77%
-60.55KRW-94.96%
-1,202.39KRW-1,204.82%
108.83KRW-80.41%
555.52KRW+36.21%
407.84KRW+74.21%
234.12KRW-35.25%
361.56KRW+63.86%
220.65KRW-178.02%
-282.82KRW+214.14%
-90.03KRW+67.95%
-53.60KRW-175.80%
70.72KRW-118.12%
-390.31KRW-3,282.34%
12.27KRW-94.57%
225.78KRW-298.60%
-113.69KRW-442.91%
33.15KRW-86.75%
250.15KRW-23.19%
325.66KRW-12.84%
373.63KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Binex Co Stock analysis

What does Binex Co do? Binex Co Ltd generates revenue through the manufacturing and sale of pharmaceutical products including digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal tract regulators, antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, and various ointments and creams. The company also produces bio medicines and raw materials. Binex Co Ltd distributes its products domestically within Busan and to overseas markets, targeting healthcare providers, pharmacies, and hospitals that purchase pharmaceuticals for patient care and treatment. The firm's product portfolio covers a wide range of therapeutic areas, including gastrointestinal health, cardiovascular support, pain management, respiratory care, and chronic disease management. By offering both branded and generic pharmaceutical solutions, Binex Co Ltd serves diverse customer segments across the domestic and international pharmaceutical markets, leveraging its manufacturing capabilities to meet regional healthcare demands. Binex Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Binex Co stock

EBIT per Share of Binex Co is -60.55 KRW in 2025.

EBIT per Share of Binex Co changed from -1,202.39 KRW to -60.55 KRW, representing a -94.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Binex Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Binex Co

All Key Metrics — Binex Co